Translate this page into:
Letter to Editor
doi:
10.4103/2278-330X.105867
Tamoxifen-induced endometrial carcinoma after a lag of 14 years
1
Department of Radiation Oncology, Regional Cancer Centre, Rohtak, Haryana
2
Department of Pathology, PGIMS Rohtak, Haryana
*Corresponding author: Dr. Anil Kumar Dhull. anildhull@sify.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/.
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 1996;39:629-40.
- Chauhan AK, Dhull AK, Singh H. Carcinoma Endometrium. Obstet Gynecol Today 2008;13:165-71.
- Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996;137:1089-95.
- Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999;131:127-35.